HONLIV HEALTH (09906) announced its interim results for 2025, reporting revenue of 347 million yuan (RMB), representing a 16.5% year-over-year decline. The company recorded a loss attributable to shareholders of 673,000 yuan, compared to a profit attributable to shareholders of 20.042 million yuan in the corresponding period last year, marking a shift from profit to loss.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.